Company / Total Assets
NovaBay Pharmaceuticals, Inc. Total Assets History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$3.4M
FY2024
5-year range
$3.4M / $24.0M
FY2020-FY2024
Trend
-62.1%
vs FY2023
Sector context
#215 of 216
Health Care
What the data says
Among 216 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the bottom 0% for total assets. Total Assets has declined for 3 consecutive years, from $24M in FY2021 to $3M in FY2024.
Based on SEC 10-K filings.
$3M in FY2024 with a 5-year CAGR of -21.1%.
Declined from $16M to $3M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -47.7%
- 5-Year CAGR
- -21.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 216This company $3.4M Sector average $7.4B
▼
-100.0% below sector average
Key checks
Key Insights
- NovaBay Pharmaceuticals, Inc.'s total assets has declined for 3 consecutive years.
- 5-year CAGR of -21.1%, indicating a declining trend.
- In FY2024, total assets decreased 62.1% year-over-year.
- Ranks #215 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $3.4M | -62.1% |
| FY2023 | $9.0M | -44.9% |
| FY2022 | $16.4M | -31.6% |
| FY2021 | $24.0M | +57.4% |
| FY2020 | $15.2M | +35.8% |
| FY2019 | $11.2M | +19.9% |
| FY2018 | $9.4M | -7.1% |
| FY2017 | $10.1M | -34.5% |
| FY2016 | $15.4M | +203.0% |
| FY2015 | $5.1M | -32.6% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026